{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:20:26Z","timestamp":1772857226230,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ejps.2022.106366","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:20:08Z","timestamp":1671589208000},"page":"106366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["In-vitro dynamic dissolution\/bioconversion\/permeation of fosamprenavir using a novel tool with an artificial biomimetic permeation barrier and microdialysis-sampling"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-3000","authenticated-orcid":false,"given":"Jonas Borregaard","family":"Eriksen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeppe Juhl","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Bauer-Brandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Ruponen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarkko","family":"Rautio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-5016","authenticated-orcid":false,"given":"Martin","family":"Brandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2022.106366_bib0001","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejps.2019.01.001","article-title":"Investigations of the mechanism behind the rapid absorption of nano-amorphous abiraterone acetate","volume":"129","author":"Basa-D\u00e9nes","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2022.106366_bib0002","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0301-0082(90)90027-E","article-title":"Microdialysis\u2014theory and application","volume":"35","author":"Benveniste","year":"1990","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejps.2022.106366_bib0003","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejps.2018.04.016","article-title":"Drug permeability profiling using cell-free permeation tools: overview and applications","volume":"119","author":"Berben","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2022.106366_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijpharm.2017.12.025","article-title":"The artificial membrane insert system as predictive tool for formulation performance evaluation","volume":"537","author":"Berben","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejps.2022.106366_bib0005","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpb.2012.07.009","article-title":"Drug precipitation\u2013permeation interplay: Supersaturation in an absorptive environment","volume":"82","author":"Bevernage","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2022.106366_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.104967","article-title":"Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems","volume":"137","author":"Boyd","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2022.106366_bib0007","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijpharm.2006.12.011","article-title":"In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation","volume":"336","author":"Brouwers","year":"2007","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.ejps.2022.106366_bib0008","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s11095-007-9307-3","article-title":"Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state","volume":"24","author":"Brouwers","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2022.106366_bib0009","unstructured":"EMA. (2004). Telzir. Retrieved 05\/07-2022 from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/telzir."},{"issue":"4","key":"10.1016\/j.ejps.2022.106366_bib0010","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3390\/pharmaceutics14040721","article-title":"Modulation of paracellular-like drug transport across an artificial biomimetic barrier by osmotic stress-induced liposome shrinking","volume":"14","author":"Eriksen","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2022.106366_bib0011","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejps.2016.09.018","article-title":"A novel microdialysis-dissolution\/permeation system for testing oral dosage forms: a proof-of-concept study","volume":"96","author":"Fong","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2022.106366_bib0012","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijpharm.2012.08.014","article-title":"Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: True supersaturation vs. apparent solubility enhancement","volume":"437","author":"Frank","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejps.2022.106366_bib0013","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejps.2012.04.015","article-title":"Impact of FaSSIF on the solubility and dissolution-\/permeation rate of a poorly water-soluble compound","volume":"47","author":"Frank","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejps.2022.106366_bib0014","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/jps.23979","article-title":"What is the mechanism behind increased permeation rate of a poorly soluble drug from aqueous dispersions of an amorphous solid dispersion?","volume":"103","author":"Frank","year":"2014","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2022.106366_bib0015","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/AAC.48.3.791-798.2004","article-title":"Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir","volume":"48","author":"Furfine","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejps.2022.106366_bib0016","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1021\/acs.molpharmaceut.7b00740","article-title":"Absorptive dissolution testing of supersaturating systems: impact of absorptive sink conditions on solution phase behavior and mass transport","volume":"14","author":"Hate","year":"2017","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.ejps.2022.106366_bib0017","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejps.2008.08.004","article-title":"Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories","volume":"35","author":"Hayeshi","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejps.2022.106366_bib0018","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1023\/A:1023827017224","article-title":"Absorption rate limit considerations for oral phosphate prodrugs","volume":"20","author":"Heimbach","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2022.106366_bib0019","article-title":"Microdialysis and nanofiltration allow to distinguish molecularly dissolved from colloid- associated drug concentrations during biomimetic dissolution testing of supersaturating formulations","volume":"106166","author":"Holzem","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2022.106366_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105452","article-title":"Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across permeapad membrane and in vivo absorption","volume":"152","author":"Ilie","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2022.106366_bib0021","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-5173(01)00897-3","article-title":"Simulated intestinal fluid as transport medium in the Caco-2 cell culture model","volume":"232","author":"Ingels","year":"2002","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.ejps.2022.106366_bib0022","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/j.2042-7158.2010.01172.x","article-title":"In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier","volume":"62","author":"Kanzer","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2022.106366_bib0023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd2796","article-title":"The influence of lead discovery strategies on the properties of drug candidates","volume":"8","author":"Keser\u00fc","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.ejps.2022.106366_bib0024","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1021\/acs.jmedchem.5b01923","article-title":"FimH antagonists: phosphate prodrugs improve oral bioavailability","volume":"59","author":"Kleeb","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2022.106366_bib0025","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jpba.2017.07.022","article-title":"Surfactants enhance recovery of poorly soluble drugs during microdialysis sampling: implications for in vitro dissolution-\/permeation-studies","volume":"145","author":"Koplin","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2022.106366_bib0026","doi-asserted-by":"crossref","unstructured":"Ostwald, W. (1897). Studien \u00fcber die Bildung und Umwandlung fester K\u00f6rper. 1. Abhandlung: \u00dcbers\u00e4ttigung und \u00dcberkaltung, 22U(1), 289-330. 10.1515\/zpch-1897-2233 (Zeitschrift f\u00fcr Physikalische Chemie).","DOI":"10.1515\/zpch-1897-2233"},{"issue":"1","key":"10.1016\/j.ejps.2022.106366_bib0027","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2017.03.002","article-title":"Evaluation of a dynamic dissolution\/permeation model: Mutual influence of dissolution and barrier-flux under non-steady state conditions","volume":"522","author":"Sironi","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2022.106366_bib0028","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejps.2016.09.001","article-title":"Dynamic dissolution-\/permeation-testing of nano- and microparticle formulations of fenofibrate","volume":"96","author":"Sironi","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2022.106366_bib0029","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jpba.2018.04.042","article-title":"PermeaLoop\u2122, a novel in vitro tool for small-scale drug-dissolution\/permeation studies","volume":"156","author":"Sironi","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2022.106366_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2015.01.001","article-title":"Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: in vitro, rat in situ and human in vivo studies","volume":"90","author":"Stappaerts","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.ejps.2022.106366_bib0031","doi-asserted-by":"crossref","first-page":"G14","DOI":"10.1152\/ajpgi.1989.257.1.G14","article-title":"Intestinal alkaline phosphatase is secreted bidirectionally from villous enterocytes","volume":"257","author":"Sussman","year":"1989","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejps.2022.106366_bib0032","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.addr.2021.02.001","article-title":"Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network","volume":"171","author":"Vinarov","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"7","key":"10.1016\/j.ejps.2022.106366_bib0033","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat. Rev. Drug Disov."},{"issue":"7","key":"10.1016\/j.ejps.2022.106366_bib0034","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1124\/dmd.108.026245","article-title":"Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs","volume":"37","author":"Yuan","year":"2009","journal-title":"Drug Metab. Dispos."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722002512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722002512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:05:49Z","timestamp":1760529949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098722002512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":34,"alternative-id":["S0928098722002512"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106366","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vitro dynamic dissolution\/bioconversion\/permeation of fosamprenavir using a novel tool with an artificial biomimetic permeation barrier and microdialysis-sampling","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106366"}}